基于模型的结核病爆发调查的影响、成本和成本效益分析,美国

IF 7.2 2区 医学 Q1 IMMUNOLOGY
Sourya Shrestha, Lucia Cilloni, Garrett R. Beeler Asay, J. Steve Kammerer, Kala Raz, Tambi Shaw, Martin Cilnis, Jonathan Wortham, Suzanne M. Marks, David Dowdy
{"title":"基于模型的结核病爆发调查的影响、成本和成本效益分析,美国","authors":"Sourya Shrestha, Lucia Cilloni, Garrett R. Beeler Asay, J. Steve Kammerer, Kala Raz, Tambi Shaw, Martin Cilnis, Jonathan Wortham, Suzanne M. Marks, David Dowdy","doi":"10.3201/eid3103.240633","DOIUrl":null,"url":null,"abstract":"<p>Outbreak investigation is an essential component of tuberculosis (TB) control in the United States, but its epidemiologic impact and cost-effectiveness have not been quantified. We modeled outbreak investigation activities in the United States during 2023–2032 and estimated corresponding epidemiologic impact, economic costs (in 2022 US$), and incremental cost-effectiveness ratios from the healthcare system perspective (cost per additional quality-adjusted life-year gained). We projected that outbreak investigations would result in 1,030,000 (95% uncertainty interval [UI] 376,000–1,740,000) contacts investigated, leading to 4,130 (95% UI 1,420–7,640) TB diagnoses and 104,000 (95% UI 37,600–181,000) latent TB infection diagnoses, at a total cost of US $219 million (95% UI $80–$387 million). We estimated that 5,560 (95% UI 1,720–11,400) TB cases would be averted through early detection and treatment, and the incremental cost-effectiveness of outbreak investigations, compared with no outbreak investigations, was $27,800 per quality-adjusted life-year gained (95% UI $4,580–$68,700).</p>","PeriodicalId":11595,"journal":{"name":"Emerging Infectious Diseases","volume":"17 1","pages":""},"PeriodicalIF":7.2000,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Model-Based Analysis of Impact, Costs, and Cost-Effectiveness of Tuberculosis Outbreak Investigations, United States\",\"authors\":\"Sourya Shrestha, Lucia Cilloni, Garrett R. Beeler Asay, J. Steve Kammerer, Kala Raz, Tambi Shaw, Martin Cilnis, Jonathan Wortham, Suzanne M. Marks, David Dowdy\",\"doi\":\"10.3201/eid3103.240633\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Outbreak investigation is an essential component of tuberculosis (TB) control in the United States, but its epidemiologic impact and cost-effectiveness have not been quantified. We modeled outbreak investigation activities in the United States during 2023–2032 and estimated corresponding epidemiologic impact, economic costs (in 2022 US$), and incremental cost-effectiveness ratios from the healthcare system perspective (cost per additional quality-adjusted life-year gained). We projected that outbreak investigations would result in 1,030,000 (95% uncertainty interval [UI] 376,000–1,740,000) contacts investigated, leading to 4,130 (95% UI 1,420–7,640) TB diagnoses and 104,000 (95% UI 37,600–181,000) latent TB infection diagnoses, at a total cost of US $219 million (95% UI $80–$387 million). We estimated that 5,560 (95% UI 1,720–11,400) TB cases would be averted through early detection and treatment, and the incremental cost-effectiveness of outbreak investigations, compared with no outbreak investigations, was $27,800 per quality-adjusted life-year gained (95% UI $4,580–$68,700).</p>\",\"PeriodicalId\":11595,\"journal\":{\"name\":\"Emerging Infectious Diseases\",\"volume\":\"17 1\",\"pages\":\"\"},\"PeriodicalIF\":7.2000,\"publicationDate\":\"2025-02-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Emerging Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3201/eid3103.240633\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Emerging Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3201/eid3103.240633","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

疫情调查是美国结核病控制的重要组成部分,但其流行病学影响和成本效益尚未量化。我们模拟了2023-2032年美国的疫情调查活动,并从医疗保健系统的角度估计了相应的流行病学影响、经济成本(以2022年美元计)和增量成本效益比(每增加质量调整生命年的成本)。我们预计疫情调查将导致103万(95%不确定区间[UI] 37.6万- 174万)接触者被调查,导致4130例(95% UI为1420 - 7640)结核诊断和10.4万例(95% UI为37600 - 18.1万)潜伏结核感染诊断,总费用为2.19亿美元(95% UI为8000 - 3.87亿美元)。我们估计,通过早期发现和治疗将避免5,560例(95% UI为1,720-11,400)结核病病例,与不进行疫情调查相比,疫情调查的增量成本效益为每质量调整生命年增加27,800美元(95% UI为4,580 - 68,700美元)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Model-Based Analysis of Impact, Costs, and Cost-Effectiveness of Tuberculosis Outbreak Investigations, United States

Outbreak investigation is an essential component of tuberculosis (TB) control in the United States, but its epidemiologic impact and cost-effectiveness have not been quantified. We modeled outbreak investigation activities in the United States during 2023–2032 and estimated corresponding epidemiologic impact, economic costs (in 2022 US$), and incremental cost-effectiveness ratios from the healthcare system perspective (cost per additional quality-adjusted life-year gained). We projected that outbreak investigations would result in 1,030,000 (95% uncertainty interval [UI] 376,000–1,740,000) contacts investigated, leading to 4,130 (95% UI 1,420–7,640) TB diagnoses and 104,000 (95% UI 37,600–181,000) latent TB infection diagnoses, at a total cost of US $219 million (95% UI $80–$387 million). We estimated that 5,560 (95% UI 1,720–11,400) TB cases would be averted through early detection and treatment, and the incremental cost-effectiveness of outbreak investigations, compared with no outbreak investigations, was $27,800 per quality-adjusted life-year gained (95% UI $4,580–$68,700).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Emerging Infectious Diseases
Emerging Infectious Diseases 医学-传染病学
CiteScore
17.30
自引率
1.70%
发文量
505
审稿时长
1 months
期刊介绍: Emerging Infectious Diseases is a monthly open access journal published by the Centers for Disease Control and Prevention. The primary goal of this peer-reviewed journal is to advance the global recognition of both new and reemerging infectious diseases, while also enhancing our understanding of the underlying factors that contribute to disease emergence, prevention, and elimination. Targeted towards professionals in the field of infectious diseases and related sciences, the journal encourages diverse contributions from experts in academic research, industry, clinical practice, public health, as well as specialists in economics, social sciences, and other relevant disciplines. By fostering a collaborative approach, Emerging Infectious Diseases aims to facilitate interdisciplinary dialogue and address the multifaceted challenges posed by infectious diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信